Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
137M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
18.9M
-
Shares change
-
+9.56M
-
Total reported value, excl. options
-
$21.7M
-
Value change
-
+$10.8M
-
Number of buys
-
49
-
Number of sells
-
-15
-
Price
-
$1.15
Significant Holders of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) as of Q2 2025
78 filings reported holding LUCD - Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.9M shares
of 137M outstanding shares and own 13.8% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (4.13M shares), BlackRock, Inc. (3.62M shares), MASTERS CAPITAL MANAGEMENT LLC (2.73M shares), GEODE CAPITAL MANAGEMENT, LLC (1.58M shares), LUMINUS MANAGEMENT LLC (795K shares), Alyeska Investment Group, L.P. (738K shares), STATE STREET CORP (623K shares), NORTHERN TRUST CORP (529K shares), MORGAN STANLEY (467K shares), and Lido Advisors, LLC (383K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.